Area riservata
Wiki Oncologia
- Le varianti di un solo gene all’origine dei tumori della pelle e del glioma
- Identificata all’Istituto Gaslini una nuova strategia per il trattamento dei tumori polmonari
- Studio IARC: molti tumori hanno origine dalle infezioni
- Tumore: una patologia sempre più cronica e di massa. Preoccupano le differenze regionali nelle opportunità di cura per i pazienti
- Tumore del seno: “Serve uno screening personalizzato. Mammografia anche alle quarantenni e alle over 70”
- Efficacia della radioterapia intraoperatoria nel carcinoma prostatico
- Una foto dell'epi-genoma per la terapia personalizzata dei tumori
- Nello Zebrafish il modello per colpire Ras, un gene alla base di tumori e malattie genetiche
- Modelli molecolari per predire quale farmaco può meglio funzionare nella cura di alcuni tumori
- Istituto Regina Elena: dalla ricerca di laboratorio una nuova arma per la lotta contro il carcinoma ovarico
Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer |
Scritto da Annals of Oncology - current issue |
Background
With the growing and evolving role of palliative care in oncology, we examined how supportive care (SC) and best supportive care (BSC) are implemented in clinical trials when used as a comparison treatment arm. MethodsWe conducted a systematic review of the literature for clinical trials published between 1980 and 2012 in which systemic anticancer therapy was compared with an SC-only arm and compared SC implementation with World Health Organization (WHO) published guidelines. ResultsOur search identified 189 articles, 73 of which met our inclusion criteria with the following cancer types: 29 lung, 7 colorectal, 6 pancreatic, 5 gastric and 26 others. Fifty-five studies (75%) provided some definition of SC, and 48 studies (66%) used the term BSC. Twenty-one of the 55 studies that provided a definition described the use of palliative therapies as being ‘at the discretion of the treating physician’ without standardization. Only two studies provided SC that incorporated routine physical, psychological and social assessments including rapid referral to SC specialists. SC interventions most commonly included analgesics (47%) and radiotherapy (44%). Trials using the term BSC versus SC were more likely to include blood transfusions (P = 0.002) and antibiotics (P = 0.033), but less likely to include steroids (P = 0.05) and palliative specialists (P = 0.047). ConclusionsThe implementation of SC in clinical trials in this systematic review is highly variable. The vast majority of the studies did not meet the WHO guidelines on SC because palliative care therapies were not recommended or integrated into care. Future clinical trials utilizing a SC intervention arm should define these interventions in a standardized approach that meets current guidelines such as the WHO recommendations. Fonte: Annals of Oncology - current issue |